Edwards Lifesciences stock trades steadily as TAVR growth and margin strength support valuation

Edwards Lifesciences stock reflects a medtech growth story driven by structural heart therapies, with investors closely watching how revenue growth and margins translate into long term value.

According to the companys most recent full year report for 2024, Edwards Lifesciences generated net sales of about $5.8 billion, up from roughly $5.4 billion in 2023, illustrating mid single digit expansion in its global structural heart and critical care portfolio.

Within that figure, transcatheter aortic valve replacement, or TAVR, remains the largest contributor, and recent disclosures indicate that TAVR related revenue climbed by a mid single digit percentage year over year, underscoring continued uptake of minimally invasive heart valve procedures in key markets including the United States, Europe, and Asia.

Investors also pay close attention to profitability, and Edwards Lifesciences reported an operating margin near the low thirties percent range for 2024, broadly consistent with the prior year, as higher sales volume and disciplined spending allowed the company to absorb increased research, development, and commercialization costs.

For many investors, the combination of growing transcatheter valve revenue and stable operating margin is central to the Edwards Lifesciences equity story, suggesting that the company is able to expand its top line without sacrificing profitability in a highly regulated and innovation driven medical device sector.

Revenue up around 7 percent

Edwards Lifesciences most recent annual data show net sales rising by approximately 7 percent year over year, from roughly $5.4 billion in 2023 to about $5.8 billion in 2024, a pace that places the company among the faster growing large cap cardiovascular device firms.

This growth was driven largely by the structural heart segment, where TAVR procedures continue to gain share against surgical aortic valve replacement in appropriate patient populations, helping to lift segment revenue by a high single digit percentage compared with 2023.

By contrast, revenue from critical care monitoring solutions, which include hemodynamic monitoring systems and related disposables, grew more modestly in the low single digit range, reflecting a more mature installed base and hospital capital spending dynamics.

For investors, the quantified comparison between 2023 and 2024 sales confirms that growth is not purely narrative but visible in the reported numbers, supporting the current valuation of Edwards Lifesciences stock in the context of broader medtech sector performance.

Profitability and EPS expansion

Beyond revenue, Edwards Lifesciences delivered solid earnings performance in 2024, reporting diluted earnings per share in the neighborhood of $3.00, up from roughly $2.70 in 2023, representing EPS growth of around 11 percent year over year.

This EPS expansion outpaced the reported top line growth and reflects operating leverage, as gross margin remained strong, above 75 percent, and selling, general, and administrative expenses grew more slowly than revenue.

The company also continued to invest heavily in research and development, dedicating around 17 percent of net sales to R and D in 2024, compared with approximately 16 percent in 2023, underscoring a commitment to sustaining its innovation pipeline while still delivering expanding earnings.

For investors assessing Edwards Lifesciences stock, the ability to increase EPS faster than revenue, while keeping gross margin high and funding substantial R and D, is a key signal that the business model can support both growth and profitability over the long term.

SAPIEN transcatheter valve franchise

A central product line for Edwards Lifesciences is the SAPIEN family of transcatheter heart valves, which are used primarily in TAVR procedures to replace a diseased aortic valve via a minimally invasive catheter based approach rather than open heart surgery.

The company has reported that SAPIEN valves and related delivery systems represent the majority of its structural heart revenue, and recent years have seen steady procedure growth as clinical guidelines broaden and more patients are considered eligible for TAVR.

In 2024, the structural heart segment, anchored by SAPIEN, contributed an estimated $4.3 billion of Edwards Lifesciences total net sales, up from around $4.0 billion in 2023, a gain of roughly 7.5 percent year over year.

For investors, the SAPIEN franchise is not only a major revenue driver but also a strategic moat, as clinical data, regulatory approvals, and physician experience create barriers to entry that help sustain Edwards Lifesciences competitive position in the transcatheter valve market.

Edwards Lifesciences stock and market context

Edwards Lifesciences stock is listed on the New York Stock Exchange under the ticker symbol EW, and the company is included in major indices that track large cap US equities, such as the S and P 500, giving it broad visibility among institutional and retail investors.

As of mid 2025, the companys market capitalization was in the region of $50 billion, reflecting investor expectations for continued growth in structural heart therapies and a premium valuation relative to many diversified medical device peers.

While specific daily price data fluctuate with overall market conditions and sector sentiment, Edwards Lifesciences shares have historically traded at a valuation multiple above the broader market, supported by its high gross margins, strong cash generation, and focused portfolio.

For investors, the market cap level and index inclusion underscore that Edwards Lifesciences stock is widely followed, and its performance can be influenced both by company specific factors, such as clinical trial results and regulatory decisions, and by macro drivers, including interest rates and healthcare spending trends.